Clinical trials: Advanced Pancreatic Carcinoma
Pancreatic Cancer
RNA Precision Oncology in Advanced Pancreatic Cancer
The overall objective of this project is to determinate the feasibility of administering personalized therapy to subjects with advanced pancreatic cancer utilizing the novel OncoTreat platform.
- Trial name
- HIPPOCRATES (NCT04476537)
- Testing
- OncoTreat
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Columbia University
Pancreatic Cancer
Trial of DN022150 Versus Chemotherapy in Previously Treated Advanced Pancreatic Cancer With KRAS G12D Mutation
This study plans to enroll participants with previously treated advanced pancreatic cancer and harbor centrally confirmed KRAS G12D mutation.
- Trial name
- NCT07689539
- Testing
- DN022150, Chemotherapy
- Volunteers
- 360 people
- Sponsor
- Jiangxi Kvvit Pharmaceutical Co., Ltd.
Resectable Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma
Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer
The purpose of this study is to evaluate the safety and efficacy of samuraciclib in patients with localized pancreatic cancer.
- Conditions
- Resectable Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT07645651
- Testing
- Samuraciclib, Computed Tomography, Endoscopic Ultrasound Biopsy
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Washington
Postoperative Complications
Clinical Outcomes of Surgery After Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer
The purpose of this study was to investigate the clinical outcomes of patients with locally advanced pancreatic cancer (LA-PC) who underwent surgery after neoadjuvant chemotherapy (NACT) at Asan Medical Center's Department of…
- Trial name
- COSNALAP (NCT05888129)
- Testing
- surgery after neoadjuvant chemotherapy
- Where
- South Korea
- Volunteers
- 1 people
- Sponsor
- Asan Medical Center
Pancreatic Ductal Adenocarcinoma, Gastroesophageal Adenocarcinoma
A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors.
The purpose of the study is to test the safety and dosing of [177Lu]Lu-FF58, a radioligand therapy for patients with advanced or metastatic tumors that express proteins known as integrins: alpha-v beta-3 integrin (αvβ3) and…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Gastroesophageal Adenocarcinoma, Glioblastoma Multiforme
- Trial name
- NCT05977322
- Testing
- 68Ga-FF58, 177Lu-FF58
- Where
- 5 sites in Israel, Netherlands and 2 more
- Volunteers
- 24 people
- Sponsor
- Novartis Pharmaceuticals
Pancreatic Adenocarcinoma, Pancreatic Cancer
Namodenoson Treatment of Advanced Pancreatic Cancer
This is an open-label trial in patients with advanced pancreatic cancer. The trial will evaluate the safety, clinical activity, and pharmacokinetics of the study drug, namodenoson, in this group of patients.
- Trial name
- NCT06387342
- Testing
- Namodenoson 25mg
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Can-Fite BioPharma
Anal Cancer, Colorectal Cancer
Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Anal Cancer, Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer
- Trial name
- NCT00003427
- Testing
- irinotecan hydrochloride, oxaliplatin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Pancreatic Adenocarcinoma Resectable, Pancreatic Adenocarcinoma Locally Advanced
Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Nab-paclitaxel (Abraxane) in Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease with conventional treatments having little impact on disease course.
- Conditions
- Pancreatic Adenocarcinoma Resectable, Pancreatic Adenocarcinoma Locally Advanced, Pancreatic Adenocarcinoma Metastatic
- Trial name
- NEOPAX-001 (NCT01715142)
- Testing
- Gemcitabine, Abraxane
- Where
- 2 sites in Belgium
- Volunteers
- 23 people
- Sponsor
- Jean-Luc Van Laethem
Pancreas Cancer, Cancer of the Pancreas
Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma
Patients with advanced pancreas adenocarcinoma will be randomized on a 6:1 basis to receive standard of care chemotherapy followed by adaptive stereotactic body radiotherapy (SBRT) with concurrent and adjuvant FAK inhibitor…
- Conditions
- Pancreas Cancer, Cancer of the Pancreas, Pancreas Adenocarcinoma
- Trial name
- NCT04331041
- Testing
- Adaptive stereotactic body radiation therapy, Defactinib, Tumor biopsy
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Washington University School of Medicine
Pancreatic Cancer
Gemcitabine, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- SCALOP (NCT01032057)
- Testing
- capecitabine, gemcitabine hydrochloride, quality-of-life assessment
- Where
- 26 sites in United Kingdom
- Volunteers
- 114 people
- Sponsor
- Lisette Nixon
Pancreatic Cancer
A Phase 1 Study Testing CP-675,206 In Combination With Gemcitabine In Patients With Previously Untreated, Advanced Pancreatic Cancer
The purpose of this study is to determine the safety and tolerability of different doses of CP-675,206 in combination with gemcitabine and to determine the maximum dose of CP-675,206 that is well tolerated when given in…
- Trial name
- NCT00556023
- Testing
- CP-675,206 and gemcitabine
- Where
- 5 sites in Canada, Italy
- Volunteers
- 37 people
- Sponsor
- AstraZeneca
Pancreatic Cancer, Cancer
Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer
This is a phase I trial to determine the maximum tolerated dose of carbon ion radiotherapy for the treatment of locally advanced, unresectable, pancreatic cancer.
- Trial name
- NCT03403049
- Testing
- Carbon Ion, Gemcitabine + Cisplatin, Gemcitabine + Capecitabine
- Where
- 2 sites in United States, China
- Volunteers
- 14 people
- Sponsor
- Montefiore Medical Center
Carcinoma, Non-Small Cell Lung, HER2 Negative Breast Neoplasms
A Study of SGN-STNV in Advanced Solid Tumors
This trial will look at a drug called SGN-STNV to find out whether it is safe for patients with solid tumors. It will study SGN-STNV to find out what its side effects are.
- Conditions
- Carcinoma, Non-Small Cell Lung, HER2 Negative Breast Neoplasms, Ovarian Neoplasms, Uterine Cervical Neoplasms
- Trial name
- NCT04665921
- Testing
- SGN-STNV
- Where
- 18 sites in United States, Canada and 4 more
- Volunteers
- 111 people
- Sponsor
- Seagen Inc.
Neoplasms, Lung Neoplasms
CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
Registry participants with advanced malignancy or myelodysplasia will have a sample of their tumor or tissue analysed for genetic alterations using next generation sequencing (NGS) performed in a lab that has been certified to…
- Conditions
- Neoplasms, Lung Neoplasms, Colon Neoplasms, Breast Neoplasms
- Trial name
- N1 (NCT02900248)
- Testing
- Provider determined
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- CureOne
Neuroendocrine Cancer
Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
The purpose of this study is to determine if carfilzomib is safe and effective in the treatment of patients with advanced neuroendocrine tumors.
- Trial name
- NCT02318784
- Testing
- Carfilzomib
- Where
- 10 sites in United States
- Volunteers
- 62 people
- Sponsor
- SCRI Development Innovations, LLC
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
This phase I trial is studying the side effects and best dose of erlotinib hydrochloride when given together with cetuximab and to see how well they work in treating patients with advanced gastrointestinal cancer, head and neck…
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
- Trial name
- NCT00397384
- Testing
- cetuximab, erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
This is a first in human (FIH) 2-part study using ACTM-838 in patients with advanced solid tumors resistant to standard of care treatment. Part 1a will evaluate dose escalation and Part 1b will evaluate dose expansion.
- Trial name
- NCT06336148
- Testing
- ACTM-838
- Where
- 5 sites in United States, Australia
- Volunteers
- 10 people
- Sponsor
- Actym Therapeutics, Inc.
Locally Advanced Pancreatic Cancer
Safety Study of Radiofrequency Ablation of Locally Advanced Pancreatic Cancer
The purpose of the study is to determine the safety of radiofrequency ablation of locally advanced pancreatic cancer that can not be surgically removed with the current standard procedures.
- Trial name
- RFA of LAPC (NCT01628458)
- Testing
- radiofrequency ablation (RFA)
- Where
- Netherlands
- Volunteers
- 17 people
- Sponsor
- UMC Utrecht
Pancreatic Cancer
Study With M2ES and Gemcitabine for Patients With Advanced Pancreatic Cancer
Phase I trail will be conducted to evaluate the safety of M2ES in combination with gemcitabine in locally advanced or metastatic pancreatic cancer.
- Trial name
- NCT01218880
- Testing
- M2ES 7.5mg, M2ES 15mg, M2ES 30mg
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Beijing Protgen Biotechnology Development Co., Ltd.
Metastatic Pancreatic Cancer
Circulating Tumor Cells as Tools for Therapy Response in Nab-paclitaxel Treated Metastatic Pancreatic Cancer Patients
The majority patients diagnosed with pancreatic cancer have metastatic disease at the time of diagnosis. The prognosis is extremely poor with a 5-year survival rate of less than 5%.
- Trial name
- PACT-ACT-v6 (NCT02707159)
- Testing
- Nab paclitaxel / gemcitabine
- Where
- Norway
- Volunteers
- 70 people
- Sponsor
- Helse Stavanger HF